Summary
Cholecystokinin was previously proposed to play an important role in the regulation of postprandial insulin secretion either indirectly, by inhibiting gastric meal emptying, or directly, by acting as an incretin promoting the release of insulin. The aim of this investigation was therefore to clarify the role of endogenous cholecystokinin in the regulation of insulin release and gastric emptying applying the highly potent and specific cholecystokinin receptor antagonist loxiglumide. Five healthy volunteers were examined after an overnight fast. Gastric meal emptying was measured by the double indicator technique using a multiple lumen tube in the duodenum and 99mTc-diethylenetriamine pentaacetate as a meal marker and polyethylene glycol 4000 as a duodenal perfusion marker. Postprandial insulin, C-peptide, cholecystokinin and glucose levels were measured after ingestion of two isocaloric meals of a) Ensure (containing fat, protein and glucose), and b) a pure glucose meal (1.11 mol/l). The meals were given either with an intravenous infusion of loxiglumide (22 μmol·kg−1·h−1) or placebo. The infusion of loxiglumide markedly accelerated the gastric emptying of the mixed meal (area under curve, 5576±352 min vs 3498±109 min; p<0.001) and the pure glucose meal (area under curve 5662±537 min vs 3551±534 min; p<0.05). Simultaneously, loxiglumide induced a more rapid rise in postprandial insulin levels after both meals resulting in significantly higher (p<0.05) insulin levels during the first postprandial hour, but similar insulin levels in the second postprandial hour. Accordingly, we found a close correlation between meal emptying and insulin release (r=0.748, p<0.01). Integrated insulin and C-peptide levels for the whole 2-h experimental period tended to be higher during loxiglumide infusion, but the difference did not reach statistical significance. Similar plasma glucose levels at all time periods were observed with and without loxiglumide infusion. Higher cholecystokinin levels were measured during loxiglumide infusion after the mixed (p<0.01) and the pure dextrose (p<0.05) meals. We conclude that postprandially released cholecystokinin exerts an important role in the regulation of gastric meal emptying and consecutively the postprandial pattern of insulin release. In contrast, no evidence was found for an insulinotropic role for cholecystokinin in man.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Liddle RA, Morita ET, Conrad CK, Williams JA (1986) Regulation of gastric emptying in humans by cholecystokinin. J Clin Invest 77: 992–996
Kleibeuker JH, Beekhuis H, Jansen JBMJ, Piers DA, Lamers CBHW (1988) Cholecystokinin is a physiological hormonal mediator of fat-induced inhibition of gastric emptying in man. Eur J Clin Invest 18: 173–177
Liddle RA, Rushakoff RJ, Morita ET, Beccaria L, Carter JD, Goldfine ID (1988) Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans. J Clin Invest 81: 1675–1681
Creutzfeldt W, Ebert R (1986) The enteroinsular axis. In: Go VLW, Gardner JD, Brooks FP, Lebenthal E, DiMagno EP, Scheele GA (eds) The exocrine pancreas. Biology, pathobiology, and diseases. Raven Press, New York, pp 333–346
Rushakoff RJ, Goldfine ID, Carter JD, Liddle RA (1987) Physiological concentrations of cholecystokinin stimulate amino acid-induced insulin release in humans. J Clin Endocrinol Metab 65: 395–401
Hildebrand P, Beglinger C, Gyr K, Jansen JBMJ, Rovati LC, Zuercher M, Lamers CBHW, Stalder GA (1990) Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man. J Clin Invest 85: 640–646
Setnikar I, Bani M, Cereda R, Chisté R, Makovec F, Pacini MA, Revel L, Rovati LC, Rovati LA (1987) Pharmacological characterization of a new potent and specific nonpolypeptidic cholecystokinin antagonist. Drug Res 37: 703–707
Setnikar I, Bani M, Cereda R, Chisté R, Makovec F, Pacini MA, Revel L (1987) Anticholecystokinin activities of loxiglumide. Drug Res 37: 1168–1171
Bartho L, Holzer P, Lembeck F, Lippe IT, Setnikar I (1987) Evaluation of a new and potent cholecystokinin antagonist on motor responses of the guinea-pig intestine. Br J Pharmac 90: 753–761
Iwamoto Y, Yamamoto R, Kuzuya T (1987) CR-1409a potent inhibitor of cholecystokinin-stimulated amylase release and cholecystokinin binding in rat pancreatic acini. Pancreas 2: 85–90
Makovec F, Bani M, Cereda R, Chisté R, Pacini MA, Revel L, Rovati LA, Rovati C, Setnikar I (1987) Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Drug Res 37: 1265–1268
Hildebrand P, Beglinger C, Gyr K, Rovati L, Setnikar I, Stalder GA (1988) Pharmacological characterization of a potent cholecystokinin (CCK) antagonist. Gastroenterology 94: 186 (Abstract)
MacGregor I, Parent J, Meyer JH (1977) Gastric emptying of liquid meals and pancreatic and biliary secretion after subtotal gastrectomy or truncal vagotomy and pyloroplasty in man. Gastroenterology 72: 195–205
Malagelada JR, Longstreth GF, Summerskill WHJ, Go VLW (1976) Measurement of gastric functions during digestion of ordinary solid meals in man. Gastroenterology 70: 203–210
Malawer SJ, Owell DW (1967) An improved turbidimetric analysis of polyethyleneglycol utilizing an emulsifier. Gastroenterology 53: 250–256
Elashoff JD, Reedy TJ, Meyer JH (1982) Analysis of gastric emptying data. Gastroenterology 83: 1306–1312
Heding L (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11: 541–548
Jansen JBMJ, Lamers CBHW (1983) Radioimmunoassay of cholecystokinin in human tissue and plasma. Clin Chim Acta 131: 305–316
Meyer BM, Werth BA, Beglinger C, Hildebrand P, Jansen JBM, Zach D, Rovati LC, Stalder GA (1989) Role of cholecystokinin in regulation of gastrointestinal motor functions. Lancet ii: 12–15
Beglinger C, Fried M, Whitehouse I, Jansen JB, Lamers CB, Gyr K (1985) Pancreatic enzyme response to a liquid meal to hormonal stimulation correlation with plasma secretin and cholecystokinin levels. J Clin Invest 75: 1471–1476
Walsh JH (1986) Gastrointestinal hormone. In: LR Johnson (ed) Physiology of the gastrointestinal tract. Raven Press, New York, pp. 181–253
Kellow JE, Millder J, Phillips SF, Haddad AC, Zinsmeister AR, Charboneau JW (1987) Sensitivities of human jejunum ileum. proximal colon and gallbladder to cholecystokinin octapeptide. Am J Physiol 252: G345-G356
Fried M, Löchner C, Erlacher U, Beglinger C, Jansen J, Lamers C, Stalder GA (1989) Role of CCK in the regulation of gastric emptying and pancreatic secretion in man. Gastroenterology 96: 159 (Abstract)
Shillabeer G, Davison JS (1987) Proglumide a cholecystokinin antagonist increases gastric emptying in rats. Am J Physiol 252: R353-R360
Hildebrand P, Beglinger C, Köhler E, Setnikar I, Gyr K (1987) Biological effects of aproglumide derivative as a cholecystokinin antagonist in conscious dogs. Regul Pept 18: 213–220
Makovec F, Bani M, Cereda R, Chisté R, Pacini MA, Revel L, Rovati LC (1987) Antispasmodic activity on the gallbladder of the mouse of CR 1409 (lorglumide) a potent antagonist of peripheral CCK. Pharmacol Res Comm 19: 41–51
Konturek SJ, Tasler J, Cieszkowski M, Szewczy K, Hladji M (1988) Effect of cholecystokinin receptor antagonist on pancreatic responses to exogenous gastrin and cholecystokinin and to meal stimuli. Gastroenterology 94: 1014–1023
Chang RSL, Lotti VJ (1986) Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc Natl Acad Sci 83: 4923–4926
Lotti VJ, Pendleton RG, Gould RJ, Hanson HM, Chang RSL, Clineschmidt BV (1987) In vivo pharmacology of L-364718 a new potent nonpeptide peripheral cholecystokinin antagonist. J Pharmacol Exp Ther 241: 103–109
Green T, Dimaline R, Peikin S, Dockray GJ (1988) Action of the cholecystokinin antagonist L364718 on gastric emptying in the rat. Am J Physiol 255: G685-G689
Bassi SL, Rovati LC, Giacovelli G, Bolondi L, Barbara L (1990) Effects of loxiglumide a cholecystokinin antagonist in non-ulcer dyspepsia. Gastroenterology 98: 77 (Abstract)
Liddle RA, Gertz BJ, Kanayama S, Beccaria L, Coker LD, Turnbull TA, Morita ET (1989) Effects of a novel cholecystokinin (CCK) receptor antagonist MK-329 on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK. J Clin Invest 84: 1220–1225
Corazziari E, Ricci R, Biliotti D, Bontempo I, De'Medici A, Pallotta N, Torsoli A (1990) Oral administration of loxiglumide (CCK antagonist) inhibits postprandial gallbladder contraction without affecting gastric emptying. Dig Dis Sci 35: 50–54
Meyer JH (1987) Motility of the stomach and gastroduodenal junction. In: Johnson LR (ed) Physiology of the gastrointestinal tract. Raven Press. New York, pp. 613–629
Tasaka Y, Sekine M, Wakatsuki M, Ohgawara H, Shizume K (1975) Levels of pancreatic glucagon insulin and glucose during twenty-four hours of the day in normal subjects. Horm Metab Res 7: 205–206
Jenkins DJA, Wolever TMS, Taylor RH, Barker H, Fielden H, Baldwin JM, Bowling AC, Newman HC, Jenkins AL, Goff DV (1981) Glycemic index of foods, a physiological basis for carbohydrate exchange. Am J Clin Nutr 34: 363–366
Creutzfeldt W, Ebert R (1985) New developments in the incretin concept. Diabetologia 28: 565–573
Sarson DL, Wood SM, Holder D, Bloom SR (1982) The effect of glucose-dependent insulinotropic polypeptide infused at physiological concentrations on the release of insulin in man. Diabetologia 22: 33–36
Sarson DL, Wood SM, Kansal PC, Bloom SR (1984) Glucosedependent insulinotropic polypeptide augmentation of insulin physiology or pharmacology? Diabetes 33: 389–393
Collier G, McLean A, O'Dea K (1984) Effect of co-ingestion of fat on the metabolic response to slowly and rapidly absorbed carbohydrates. Diabetologia 26: 50–54
Fried M, Mayer EA, Bloom SR, Taylor IL, Meyer JH (1989) GIP and insulin release in relation to gastric emptying of a mixed meal in man. Regul Pept 26: 305–312
Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-17-36: a physiological incretin in man. Lancet ii: 1300–1303
Rossetti L, Shulman GI, Zawalich WS (1987) Physiological role of cholecystokinin in meal-induced insulin secretion in conscious rats. Studies with L 364718 a specific inhibitor of CCK-receptor binding. Diabetes 36: 1212–1215
Green GM, Olds BA, Matthews G, Lyman RL (1973) Protein as a regulator of pancreatic enzyme secretion in the rat. Proc Soc Exp Biol Med 142: 1162–1167
Niederau J, Schwarzendrube J, Niederau M, Rüthen R (1990) CCK does not act as a physiologic insulinotropic factor after regular meals in healthy humans. Digestion 46 (Suppl. 1): 217 (Abstract)
Hildebrand P, Ensinck JW, Mossi S, Delco F, Gyr K, Beglinger C (1990) Cholecystokinin (CCK) is not an incretin in humans. Digestion 46: 57 (Abstract)
Bonato C, Valentini A, Tacconi M, Rovati L, Malesci A (1989) Effect of CCK-receptor blockade on the postprandial release of insular hormones. Gastroenterology 96: 51 (Abstract)
Liddle RA, Gertz BJ, Kanayama S, Beccaria L, Coker LD, Turnbull TA, Morita ET (1989) Effects of a novel cholecystokinin (CCK) receptor antagonist MK-329 on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK. J Clin Invest 84: 1220–1225
Liddle RA, Gertz BJ, Kanayama S, Beccaria L, Gettys TW, Taylor IL, Rushakoff RJ, Williams VC, Coker LD (1990) Regulation of pancreatic endocrine function by cholecystokinin: Studies with MK-329 a nonpeptide cholecystokinin receptor antagonist. J Clin Endocrinol Metab 70: 1312–1318
Slaff J, Jacobson D, Tillman CR, Curington C, Toskes P (1984) Protease-specific suppression of pancreatic exocrine secretion. Gastroenterology 87: 44–52
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fried, M., Schwizer, W., Beglinger, C. et al. Physiological role of cholecystokinin on postprandial insulin secretion and gastric meal emptying in man. Studies with the cholecystokinin receptor antagonist loxiglumide. Diabetologia 34, 721–726 (1991). https://doi.org/10.1007/BF00401517
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00401517